10. References
1. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of
human reaginic antibody: IV. Presence of a unique immunoglobulin as a
carrier of reaginic activity. The Journal of Immunology.1966;97(1):75-85.
2. Johansson S, Bennich H. Immunological studies of an atypical
(myeloma) immunoglobulin. Immunology. 1967;13(4):381.
3. Gould HJ, Sutton BJ, Beavil AJ, et al. The biology of IGE and the
basis of allergic disease. Annual review of immunology.2003;21(1):579-628.
4. Pillai P, Fang C, Chan Y-C, et al. Allergen-specific IgE is not
detectable in the bronchial mucosa of nonatopic asthmatic patients.Journal of Allergy and Clinical Immunology.2014;133(6):1770-1772. e1711.
5. Durham SR, Gould HJ, Hamid QA. Local IgE production in nasal allergy.Int Arch Allergy Immunol. 1997;113(1-3):128-130.
6. Ying S, Humbert M, Meng Q, et al. Local expression of ϵ germline gene
transcripts and RNA for the ϵ heavy chain of IgE in the bronchial mucosa
in atopic and nonatopic asthma. Journal of allergy and clinical
immunology. 2001;107(4):686-692.
7. Wilson DR, Merrett TG, Varga EM, et al. Increases in
allergen-specific IgE in BAL after segmental allergen challenge in
atopic asthmatics. American journal of respiratory and critical
care medicine. 2002;165(1):22-26.
8. Lambrecht B, Peleman R, Bullock G, Pauwels R. Sensitization to
inhaled antigen by intratracheal instillation of dendritic cells.Clinical and experimental allergy: journal of the British Society
for Allergy and Clinical Immunology. 2000;30(2):214-224.
9. Deckers J, De Bosscher K, Lambrecht BN, Hammad H. Interplay between
barrier epithelial cells and dendritic cells in allergic sensitization
through the lung and the skin. Immunological reviews.2017;278(1):131-144.
10. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B
lymphocytes can be competent antigen-presenting cells for priming CD4+ T
cells to protein antigens in vivo. The Journal of Immunology.1995;155(8):3734-3741.
11. Rivera A, Chen C-C, Ron N, Dougherty JP, Ron Y. Role of B cells as
antigen-presenting cells in vivo revisited: antigen-specific B cells are
essential for T cell expansion in lymph nodes and for systemic T cell
responses to low antigen concentrations. International
immunology. 2001;13(12):1583-1593.
12. Dullaers M, Schuijs MJ, Willart M, et al. House dust mite–driven
asthma and allergen-specific T cells depend on B cells when the amount
of inhaled allergen is limiting. Journal of Allergy and Clinical
Immunology. 2017;140(1):76-88. e77.
13. Wypych TP, Marzi R, Wu GF, Lanzavecchia A, Sallusto F. Role of B
cells in T(H) cell responses in a mouse model of asthma. J Allergy
Clin Immunol. 2018;141(4):1395-1410.
14. Scadding GW, Eifan A, Lao‐Araya M, et al. Effect of grass pollen
immunotherapy on clinical and local immune response to nasal allergen
challenge. Allergy. 2015;70(6):689-696.
15. Takhar P, Corrigan CJ, Smurthwaite L, et al. Class switch
recombination to IgE in the bronchial mucosa of atopic and nonatopic
patients with asthma. Journal of Allergy and Clinical Immunology.2007;119(1):213-218.
16. Santamaria LF, Bheekha R, van Reijsen FC, et al. Antigen focusing by
specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr
virus-transformed B cells. Hum Immunol. 1993;37(1):23-30.
17. Maurer D, Ebner C, Reininger B, et al. The high affinity IgE
receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation.The Journal of Immunology. 1995;154(12):6285-6290.
18. Maurer D, Fiebiger S, Ebner C, et al. Peripheral blood dendritic
cells express Fc epsilon RI as a complex composed of Fc epsilon RI
alpha-and Fc epsilon RI gamma-chains and can use this receptor for
IgE-mediated allergen presentation. The Journal of Immunology.1996;157(2):607-616.
19. Van der Heijden F, Van Neerven RJ, Van Katwijk M, Bos J, Kapsenberg
M. Serum-IgE-facilitated allergen presentation in atopic disease.The Journal of Immunology. 1993;150(8):3643-3650.
20. Mosconi E, Rekima A, Seitz-Polski B, et al. Breast milk immune
complexes are potent inducers of oral tolerance in neonates and prevent
asthma development. Mucosal immunology. 2010;3(5):461-474.
21. Lupinek C, Hochwallner H, Johansson C, et al. Maternal
allergen-specific IgG might protect the child against allergic
sensitization. Journal of Allergy and Clinical Immunology.2019;144(2):536-548.
22. Marchant A, Sadarangani M, Garand M, et al. Maternal immunisation:
collaborating with mother nature. The Lancet Infectious Diseases.2017;17(7):e197-e208.
23. Uthoff H, Spenner A, Reckelkamm W, et al. Critical role of
preconceptional immunization for protective and nonpathological specific
immunity in murine neonates. The Journal of Immunology.2003;171(7):3485-3492.
24. Larché M, Akdis CA, Valenta R. Immunological mechanisms of
allergen-specific immunotherapy. Nature Reviews Immunology.2006;6(10):761-771.
25. Cooke RA, Barnard JH, Hebald S, Stull A. SEROLOGICAL EVIDENCE OF
IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY
FEVER). J Exp Med. 1935;62(6):733-750.
26. Platts-Mills TA, von Maur RK, Ishizaka K, Norman PS, Lichtenstein
LM. IgA and IgG anti-ragweed antibodies in nasal secretions.
Quantitative measurements of antibodies and correlation with inhibition
of histamine release. J Clin Invest. 1976;57(4):1041-1050.
27. Shamji MH LD, Eifan A, Scadding GW, Qin T, Lawson K, SeverML,
Macfarlane E, Layhadi JA, Würtzen P, Parkin RV, Sanda S, Harris KM,
Nepom GT, Togias A, Durham SR. Differential Induction of
Allergen-specific IgA Responses following Timothy Grass Subcutaneous and
Sublingual Immunotherapy. . J Allergy Clin Immunol 2021 (in
press).
28. Wan T, Beavil RL, Fabiane SM, et al. The crystal structure of IgE Fc
reveals an asymmetrically bent conformation. Nature Immunology.2002;3(7):681-686.
29. Zheng Y, Shopes B, Holowka D, Baird B. Dynamic conformations
compared for IgE and IgG1 in solution and bound to receptors.Biochemistry. 1992;31(33):7446-7456.
30. Zheng Y, Shopes B, Holowka D, Baird B. Conformations of IgE Bound to
its Receptor Fc. epsilon. RI and in Solution. Biochemistry.1991;30(38):9125-9132.
31. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in
perennial allergic rhinitics exhibit increased expression of the Fc
epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B
cells. The Journal of clinical investigation.1997;99(7):1492-1499.
32. Cameron L, Gounni AS, Frenkiel S, Lavigne F, Vercelli D, Hamid Q.
SεSμ and SεSγ switch circles in human nasal mucosa following ex vivo
allergen challenge: evidence for direct as well as sequential class
switch recombination. The Journal of Immunology.2003;171(7):3816-3822.
33. Corry DB, Kheradmand F. Induction and regulation of the IgE
response. Nature. 1999;402(6760):18-23.
34. Humbert M, Grant JA, Taborda-Barata L, et al. High-affinity IgE
receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic
and nonatopic asthma. American journal of respiratory and critical
care medicine. 1996;153(6):1931-1937.
35. Daëron M. Fc RECEPTOR BIOLOGY. Annual Review of Immunology.1997;15(1):203-234.
36. Ravetch JV. Fc receptors. Curr Opin Immunol.1997;9(1):121-125.
37. Saini SS, Richardson JJ, Wofsy C, Lavens-Phillips S, Bochner BS,
MacGlashan DW. Expression and modulation of FcϵRIα and FcϵRIβ in human
blood basophils. Journal of Allergy and Clinical Immunology.2001;107(5):832-841.
38. Kraft S, Kinet J-P. New developments in FcεRI regulation, function
and inhibition. Nature Reviews Immunology. 2007;7(5):365-378.
39. Siraganian RP. Mast cell signal transduction from the high-affinity
IgE receptor. Current opinion in immunology. 2003;15(6):639-646.
40. Saini SS, MacGlashan DW, Sterbinsky SA, et al. Down-regulation of
human basophil IgE and FcεRIα surface densities and mediator release by
anti-IgE-infusions is reversible in vitro and in vivo. The Journal
of Immunology. 1999;162(9):5624-5630.
41. MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc
(epsilon) RI expression on human basophils during in vivo treatment of
atopic patients with anti-IgE antibody. The Journal of
Immunology. 1997;158(3):1438-1445.
42. Asai K, Kitaura J, Kawakami Y, et al. Regulation of mast cell
survival by IgE. Immunity. 2001;14(6):791-800.
43. Kinet J-P. The high-affinity IgE receptor (FcεRI): from physiology
to pathology. Annual review of immunology. 1999;17(1):931-972.
44. Rajakulasingam K, Durham SR, O’Brien F, et al. Enhanced expression
of high-affinity IgE receptor (FcϵRI) α chain in human allergen-induced
rhinitis with co-localization to mast cells, macrophages, eosinophils,
and dendritic cells. Journal of Allergy and Clinical Immunology.1997;100(1):78-86.
45. Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, MacGlashan
Jr DW. The relationship between serum IgE and surface levels of FcϵR on
human leukocytes in various diseases: correlation of expression with
FcϵRI on basophils but not on monocytes or eosinophils. Journal of
allergy and clinical immunology. 2000;106(3):514-520.
46. Allam J-P, Novak N, Fuchs C, et al. Characterization of dendritic
cells from human oral mucosa: A new Langerhans’ cell type with high
constitutive FcϵRI expression. Journal of Allergy and Clinical
Immunology. 2003;112(1):141-148.
47. Foster B, Metcalfe DD, Prussin C. Human dendritic cell 1 and
dendritic cell 2 subsets express FcεRI: correlation with serum IgE and
allergic asthma. Journal of Allergy and Clinical Immunology.2003;112(6):1132-1138.
48. Kikutani H, Inui S, Sato R, et al. Molecular structure of human
lymphocyte receptor for immunoglobulin E. Cell.1986;47(5):657-665.
49. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E
class-switch recombination. Nature Reviews Immunology.2003;3(9):721-732.
50. Lüdin C, Hofstetter H, Sarfati M, et al. Cloning and expression of
the cDNA coding for a human lymphocyte IgE receptor. The EMBO
journal. 1987;6(1):109-114.
51. Letellier M, Sarfati M, Delespesse G. Mechanisms of formation of
IgE-binding factors (soluble CD23)—I. Fcϵ R II bearing B cells
generate IgE-binding factors of different molecular weights.Molecular Immunology. 1989;26(12):1105-1112.
52. McCloskey N, Hunt J, Beavil RL, et al. Soluble CD23 Monomers Inhibit
and Oligomers Stimulate IGE Synthesis in Human B Cells*. Journal
of Biological Chemistry. 2007;282(33):24083-24091.
53. Novak N, Kraft S, Bieber T. IgE receptors. Current Opinion in
Immunology. 2001;13(6):721-726.
54. Yokota A, Yukawa K, Yamamoto A, et al. Two forms of the low-affinity
Fc receptor for IgE differentially mediate endocytosis and phagocytosis:
identification of the critical cytoplasmic domains. Proc Natl Acad
Sci U S A. 1992;89(11):5030-5034.
55. Kay AB. Paul Ehrlich and the Early History of Granulocytes.Microbiol Spectr. 2016;4(4).
56. Turner H, Kinet J-P. Signalling through the high-affinity IgE
receptor FcεRI. Nature. 1999;402(6760):24-30.
57. Wedemeyer J, Tsai M, Galli SJ. Roles of mast cells and basophils in
innate and acquired immunity. Current opinion in immunology.2000;12(6):624-631.
58. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and
eosinophils. Journal of Allergy and Clinical Immunology.2010;125(2):S73-S80.
59. Kim HS, Kawakami Y, Kasakura K, Kawakami T. Recent advances in mast
cell activation and regulation. F1000Research. 2020;9.
60. Shade K-TC, Conroy ME, Washburn N, et al. Sialylation of
immunoglobulin E is a determinant of allergic pathogenicity.Nature. 2020;582(7811):265-270.
61. Christensen LH, Holm J, Lund G, Riise E, Lund K. Several distinct
properties of the IgE repertoire determine effector cell degranulation
in response to allergen challenge. Journal of Allergy and Clinical
Immunology. 2008;122(2):298-304.
62. Hjort C, Schiøtz PO, Ohlin M, Würtzen PA, Christensen LH, Hoffmann
HJ. The number and affinity of productive IgE pairs determine allergen
activation of mast cells. Journal of Allergy and Clinical
Immunology. 2017;140(4):1167.
63. Hamilton RG, Saito H. IgE antibody concentration, specific activity,
clonality, and affinity measures from future diagnostic confirmatory
tests. Journal of Allergy and Clinical Immunology.2008;122(2):305-306.
64. Holowka D, Sil D, Torigoe C, Baird B. Insights into immunoglobulin E
receptor signaling from structurally defined ligands.Immunological reviews. 2007;217(1):269-279.
65. Gieras A, Linhart B, Roux KH, et al. IgE epitope proximity
determines immune complex shape and effector cell activation capacity.Journal of Allergy and Clinical Immunology.2016;137(5):1557-1565.
66. Gieras A, Focke-Tejkl M, Ball T, et al. Molecular determinants of
allergen-induced effector cell degranulation. Journal of allergy
and clinical immunology. 2007;119(2):384-390.
67. Mudde GC, Bheekha R, Bruijnzeel-Koomen CA. Consequences of
IgE/CD23-mediated antigen presentation in allergy. Immunology
today. 1995;16(8):380-383.
68. Reginald K, Eckl-Dorna J, Zafred D, et al. Different modes of IgE
binding to CD23 revealed with major birch allergen, Bet v 1-specific
monoclonal IgE. Immunol Cell Biol. 2013;91(2):167-172.
69. Holm J, Willumsen N, Würtzen PA, Christensen LH, Lund K. Facilitated
antigen presentation and its inhibition by blocking IgG antibodies
depends on IgE repertoire complexity. Journal of Allergy and
Clinical Immunology. 2011;127(4):1029-1037.
70. Villazala-Merino S, Rodriguez-Dominguez A, Stanek V, et al.
Allergen-specific IgE levels and the ability of IgE-allergen complexes
to cross-link determine the extent of CD23-mediated T-cell activation.Journal of Allergy and Clinical Immunology.2020;145(3):958-967.e955.
71. Selb R, Eckl-Dorna J, Twaroch TE, et al. Critical and direct
involvement of the CD23 stalk region in IgE binding. Journal of
Allergy and Clinical Immunology. 2017;139(1):281-289. e285.
72. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of
age. Nat Rev Immunol. 2007;7(9):715-725.
73. Jenmalm M, Björkstén B. Cord blood levels of immunoglobulin G
subclass antibodies to food and inhalant allergens in relation to
maternal atopy and the development of atopic disease during the first 8
years of life. Clinical and experimental allergy: journal of the
British Society for Allergy and Clinical Immunology. 2000;30(1):34-40.
74. Macchiaverni P, Arslanian C, Frazao J, et al. Mother to child
transfer of IgG and IgA antibodies against Dermatophagoides
pteronyssinus. Scandinavian journal of immunology.2011;74(6):619-627.
75. Glovsky MM, Ghekiere L, Rejzek E. Effect of maternal immunotherapy
on immediate skin test reactivity, specific rye I IgG and IgE antibody,
and total IgE of the children. Annals of allergy.1991;67(1):21-24.
76. Flicker S, Marth K, Kofler H, Valenta R. Placental transfer of
allergen-specific IgG but not IgE from a specific immunotherapy-treated
mother. Journal of Allergy and Clinical Immunology.2009;124(6):1358.
77. Oykhman P, Kim HL, Ellis AK. Allergen immunotherapy in pregnancy.Allergy, Asthma & Clinical Immunology. 2015;11(1):1-5.
78. Msallam R, Balla J, Rathore AP, et al. Fetal mast cells mediate
postnatal allergic responses dependent on maternal IgE. Science.2020;370(6519):941-950.
79. Brandtzaeg P. Mucosal immunity: integration between mother and the
breast-fed infant. Vaccine. 2003;21(24):3382-3388.
80. Rekima A, Macchiaverni P, Turfkruyer M, et al. Long‐term reduction
in food allergy susceptibility in mice by combining
breastfeeding‐induced tolerance and TGF‐β‐enriched formula after
weaning. Clinical & Experimental Allergy. 2017;47(4):565-576.
81. Ohsaki A, Venturelli N, Buccigrosso TM, et al. Maternal IgG immune
complexes induce food allergen–specific tolerance in offspring.Journal of Experimental Medicine. 2018;215(1):91-113.
82. Victor JR. Allergen-specific IgG as a mediator of allergy
inhibition: Lessons from mother to child. Human vaccines &
immunotherapeutics. 2017;13(3):507-513.
83. Casas R, Björkstén B. Detection of Fel d 1–immunoglobulin G immune
complexes in cord blood and sera from allergic and non‐allergic mothers.Pediatric allergy and immunology. 2001;12(2):59-64.
84. Bernard H, Ah‐Leung S, Drumare MF, et al. Peanut allergens are
rapidly transferred in human breast milk and can prevent sensitization
in mice. Allergy. 2014;69(7):888-897.
85. Adel-Patient K, Bernard H, Fenaille F, Hazebrouck S, Junot C,
Verhasselt V. Prevention of allergy to a major cow’s milk allergen by
breastfeeding in mice depends on maternal immune status and oral
exposure during lactation. Frontiers in immunology. 2020;11:1545.
86. López-Expósito I, Song Y, Järvinen KM, Srivastava K, Li X-M.
Maternal peanut exposure during pregnancy and lactation reduces peanut
allergy risk in offspring. Journal of allergy and clinical
immunology. 2009;124(5):1039-1046.
87. Järvinen KM, Westfall J, De Jesus M, et al. Role of maternal dietary
peanut exposure in development of food allergy and oral tolerance.PloS one. 2015;10(12):e0143855.
88. Macchiaverni P, Rekima A, Turfkruyer M, et al. Respiratory allergen
from house dust mite is present in human milk and primes for allergic
sensitization in a mouse model of asthma. Allergy.2014;69(3):395-398.
89. Rekima A, Bonnart C, Macchiaverni P, et al. A role for early oral
exposure to house dust mite allergens through breast milk in
IgE-mediated food allergy susceptibility. Journal of Allergy and
Clinical Immunology. 2020;145(5):1416-1429. e1411.
90. Collins A, Roberton D, Hosking C, Flannery G. Bovine milk, including
pasteurised milk, contains antibodies directed against allergens of
clinical importance to man. International Archives of Allergy and
Immunology. 1991;96(4):362-367.
91. Von Mutius E, Vercelli D. Farm living: effects on childhood asthma
and allergy. Nature Reviews Immunology. 2010;10(12):861-868.
92. Brick T, Hettinga K, Kirchner B, Pfaffl MW, Ege MJ. The beneficial
effect of farm milk consumption on asthma, allergies, and infections:
from meta-analysis of evidence to clinical trial. The Journal of
Allergy and Clinical Immunology: In Practice. 2020;8(3):878-889. e873.
93. Sozańska B. Raw cow’s milk and its protective effect on allergies
and asthma. Nutrients. 2019;11(2):469.
94. Machtinger S, Moss R. Cow’s milk allergy in breast-fed infants: the
role of allergen and maternal secretory IgA antibody. Journal of
allergy and clinical immunology. 1986;77(2):341-347.
95. Savilahti E, Tainio VM, Salmenperä L, et al. Low colostral IgA
associated with cow’s milk allergy. Acta Pædiatrica.1991;80(12):1207-1213.
96. Järvinen KM, Westfall JE, Seppo MS, et al. Role of maternal
elimination diets and human milk IgA in the development of cow’s milk
allergy in the infants. Clinical & Experimental Allergy.2014;44(1):69-78.
97. Jêvinen K-M, Laine ST, Jêvenpêê A-L, Suomalainen HK. Does low IgA in
human milk predispose the infant to development of cow’s milk allergy?Pediatric research. 2000;48(4):457-462.
98. Orivuori L, Loss G, Roduit C, et al. Soluble immunoglobulin A in
breast milk is inversely associated with atopic dermatitis at early age:
the PASTURE cohort study. Clinical & experimental allergy.2014;44(1):102-112.
99. Ramanan D, Sefik E, Galván-Peña S, et al. An immunologic mode of
multigenerational transmission governs a gut Treg setpoint. Cell.2020;181(6):1276-1290. e1213.
100. Bousquet J, Lockey R, Malling H-J. Allergen immunotherapy:
therapeutic vaccines for allergic diseases A WHO position paper.Journal of Allergy and Clinical Immunology. 1998;102(4):558-562.
101. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy:
clinical indications in the WAO-SLIT position paper. World Allergy
Organization Journal. 2010;3(7):216-219.
102. Hoffmann H, Valovirta E, Pfaar O, et al. Novel approaches and
perspectives in allergen immunotherapy. Allergy.2017;72(7):1022-1034.
103. Gunawardana NC, Durham SR. New approaches to allergen
immunotherapy. Annals of Allergy, Asthma & Immunology.2018;121(3):293-305.
104. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of
immunotherapy on immunoglobulin E and immunoglobulin G antibodies to
ragweed antigens: a six-year prospective study. Journal of Allergy
and Clinical Immunology. 1982;70(4):261-271.
105. Shamji M, Kappen J, Akdis M, et al. Biomarkers for monitoring
clinical efficacy of allergen immunotherapy for allergic
rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.Allergy. 2017;72(8):1156-1173.
106. Shamji MH, Kappen J, Abubakar-Waziri H, et al. Nasal
allergen-neutralizing IgG4 antibodies block IgE-mediated responses:
Novel biomarker of subcutaneous grass pollen immunotherapy.Journal of Allergy and Clinical Immunology.2019;143(3):1067-1076.
107. Matricardi PM, Dramburg S, Potapova E, Skevaki C, Renz H. Molecular
diagnosis for allergen immunotherapy. Journal of Allergy and
Clinical Immunology. 2019;143(3):831-843.
108. Rodríguez-Domínguez A, Berings M, Rohrbach A, et al. Molecular
profiling of allergen-specific antibody responses may enhance success of
specific immunotherapy. Journal of Allergy and Clinical
Immunology. 2020;146(5):1097-1108.
109. Van Der Zee JS, Van Swieten P, Aalberse R. Serologic aspects of
IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune
complexes due to functional monovalency. The Journal of
Immunology. 1986;137(11):3566-3571.
110. van der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting
of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute
myeloid leukemia: in vivo and in vitro saturation and internalization by
leukemic and normal myeloid cells. Blood, The Journal of the
American Society of Hematology. 2001;97(10):3197-3204.
111. Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen
immunotherapy induces an allergen-specific IgA2 antibody response
associated with mucosal TGF-β expression. The Journal of
Immunology. 2007;178(7):4658-4666.
112. Lupinek C, Wollmann E, Valenta R. Monitoring allergen immunotherapy
effects by microarray. Current treatment options in allergy.2016;3(2):189-203.
113. Van Neerven R, Wikborg T, Lund G, et al. Blocking antibodies
induced by specific allergy vaccination prevent the activation of CD4+ T
cells by inhibiting serum-IgE-facilitated allergen presentation.The Journal of Immunology. 1999;163(5):2944-2952.
114. Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A
double-blind placebo-controlled birch allergy vaccination study II:
correlation between inhibition of IgE binding, histamine release and
facilitated allergen presentation. Clin Exp Allergy.2008;38(8):1290-1301.
115. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of
allergen-IgE binding to B cells by IgG antibodies after grass pollen
immunotherapy. Journal of Allergy and Clinical Immunology.2003;112(5):915-922.
116. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after
allergen immunotherapy is accompanied by selective persistence of
blocking antibodies. Journal of Allergy and Clinical Immunology.2011;127(2):509-516. e505.
117. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen
immunotherapy induces mucosal and peripheral IL-10 responses and
blocking IgG activity. The Journal of Immunology.2004;172(5):3252-3259.
118. Heeringa JJ, McKenzie CI, Varese N, et al. Induction of IgG2 and
IgG4 B‐cell memory following sublingual immunotherapy for ryegrass
pollen allergy. Allergy. 2020;75(5):1121-1132.
119. Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated
allergen binding (FAB) assay: validation of a novel flow-cytometric
based method for the detection of inhibitory antibody responses.Journal of immunological methods. 2006;317(1-2):71-79.
120. Shamji M, Ljørring C, Francis J, et al. Functional rather than
immunoreactive levels of IgG4 correlate closely with clinical response
to grass pollen immunotherapy. Allergy. 2012;67(2):217-226.
121. Valenta R, Campana R, Niederberger V. Recombinant allergy vaccines
based on allergen-derived B cell epitopes. Immunology letters.2017;189:19-26.
122. Valenta R, Karaulov A, Niederberger V, et al. Molecular aspects of
allergens and allergy. Advances in immunology. 2018;138:195-256.
123. Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen
immunotherapy: IL-10 induction and suppression of late responses
precedes IgG4 inhibitory antibody activity. Journal of Allergy and
Clinical Immunology. 2008;121(5):1120-1125. e1122.
124. Rauber MM, Wu HK, Adams B, et al. Birch pollen allergen‐specific
immunotherapy with glutaraldehyde‐modified allergoid induces IL‐10
secretion and protective antibody responses. Allergy.2019;74(8):1575-1579.
125. Ejrnaes A, Svenson M, Lund G, Larsen J, Jacobi H. Inhibition of
rBet v 1‐induced basophil histamine release with specific
immunotherapy‐induced serum immunoglobulin G: no evidence that FcγRIIB
signalling is important. Clinical & Experimental Allergy.2006;36(3):273-282.
126. Shamji MH, Layhadi JA, Scadding GW, et al. Basophil expression of
diamine oxidase: a novel biomarker of allergen immunotherapy response.Journal of Allergy and Clinical Immunology. 2015;135(4):913-921.
e919.
127. Korosec P, Erzen R, Silar M, Bajrovic N, Kopac P, Kosnik M.
Basophil responsiveness in patients with insect sting allergies and
negative venom‐specific immunoglobulin E and skin prick test results.Clinical & Experimental Allergy. 2009;39(11):1730-1737.
128. Orengo J, Radin A, Kamat V, et al. Treating cat allergy with
monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Nature communications. 2018;9(1):1-15.
129. Shamji MH, Singh I, Layhadi JA, et al. Passive Prophylactic
Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies
REGN1908-1909 in Cat Allergen-Induced Allergic Rhinitis: A Randomized,
Double-blind, Placebo Controlled Trial. American Journal of
Respiratory and Critical Care Medicine. 2021(ja).
130. Van Neerven R, Van Roomen C, Thomas W, De Boer M, Knol E, Davis F.
Humanized anti-IgE mAb Hu-901 prevents the activation of
allergen-specific T cells. International archives of allergy and
immunology. 2001;124(1-3):400-402.
131. Dhaliwal B, Yuan D, Pang MO, et al. Crystal structure of IgE bound
to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric
inhibition with high affinity receptor FcεRI. Proceedings of the
National Academy of Sciences. 2012;109(31):12686-12691.
132. McDonnell JM, Calvert R, Beavil RL, et al. The structure of the IgE
Cɛ2 domain and its role in stabilizing the complex with its
high-affinity receptor FcɛRIα. Nature structural biology.2001;8(5):437-441.
133. Wurzburg BA, Garman SC, Jardetzky TS. Structure of the human IgE-Fc
Cε3-Cε4 reveals conformational flexibility in the antibody effector
domains. Immunity. 2000;13(3):375-385.
134. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE
recombinant humanized monoclonal antibody, for the treatment of severe
allergic asthma. Journal of allergy and clinical immunology.2001;108(2):184-190.
135. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics,
pharmacodynamics and safety of QGE 031 (ligelizumab), a novel
high‐affinity anti‐IgE antibody, in atopic subjects. Clinical &
Experimental Allergy. 2014;44(11):1371-1385.
136. Gasser P, Eggel A. Targeting IgE in allergic disease. Current
opinion in immunology. 2018;54:86-92.
137. Cox L. Biologics and Allergy Immunotherapy in the Treatment of
Allergic Diseases. Immunology and Allergy Clinics.2020;40(4):687-700.
138. Lin C, Lee IT, Sampath V, et al. Combining anti‐IgE with oral
immunotherapy. Pediatric Allergy and Immunology.2017;28(7):619-627.
139. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and
functional profile of the therapeutic anti-IgE antibody ligelizumab
differs from omalizumab. Nature communications. 2020;11(1):1-14.
140. Gauvreau GM, Arm JP, Boulet L-P, et al. Efficacy and safety of
multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in
inhibiting allergen-induced early asthmatic responses. Journal of
Allergy and Clinical Immunology. 2016;138(4):1051-1059.
141. Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for
chronic spontaneous urticaria. New England Journal of Medicine.2019;381(14):1321-1332.
142. Pennington LF, Tarchevskaya S, Brigger D, et al. Structural basis
of omalizumab therapy and omalizumab-mediated IgE exchange. Nature
communications. 2016;7(1):1-12.
143. Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of
action of the therapeutic anti-IgE antibody omalizumab. Journal of
Biological Chemistry. 2017;292(24):9975-9987.
144. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nature
Reviews Immunology. 2008;8(3):205-217.
145. Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C.
Central role of immunoglobulin (Ig) E in the induction of lung
eosinophil infiltration and T helper 2 cell cytokine production:
inhibition by a non-anaphylactogenic anti-IgE antibody. The
Journal of experimental medicine. 1996;183(4):1303-1310.
146. Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC.
Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I,
single-dose, dose-escalating clinical trial. Journal of Allergy
and Clinical Immunology. 2003;112(3):563-570.
147. Virkud YV, Wang J, Shreffler WG. Enhancing the safety and efficacy
of food allergy immunotherapy: a review of adjunctive therapies.Clinical reviews in allergy & immunology. 2018;55(2):172-189.
148. Dantzer J, Wood RA. The use of omalizumab in allergen
immunotherapy. Clinical & Experimental Allergy.2018;48(3):232-240.
149. Kim B, Tarchevskaya SS, Eggel A, Vogel M, Jardetzky TS. A
time-resolved fluorescence resonance energy transfer assay suitable for
high-throughput screening for inhibitors of immunoglobulin E–receptor
interactions. Analytical Biochemistry. 2012;431(2):84-89.
150. Eggel A, Baravalle G, Hobi G, et al. Accelerated dissociation of
IgE-FcεRI complexes by disruptive inhibitors actively desensitizes
allergic effector cells. Journal of allergy and clinical
immunology. 2014;133(6):1709-1719. e1708.
151. Campana R, Marth K, Zieglmayer P, et al. Vaccination of nonallergic
individuals with recombinant hypoallergenic fragments of birch pollen
allergen Bet v 1: safety, effects, and mechanisms. Journal of
Allergy and Clinical Immunology. 2019;143(3):1258-1261.
152. van Hage M, Hamsten C, Valenta R. ImmunoCAP assays: Pros and cons
in allergology. Journal of Allergy and Clinical Immunology.2017;140(4):974-977.
153. Skrindo I, Lupinek C, Valenta R, et al. The use of the MeDALL-chip
to assess IgE sensitization: a new diagnostic tool for allergic disease?Pediatr Allergy Immunol. 2015;26(3):239-246.
154. Lupinek C, Wollmann E, Baar A, et al. Advances in
allergen-microarray technology for diagnosis and monitoring of allergy:
the MeDALL allergen-chip. Methods. 2014;66(1):106-119.
155. Wollmann E, Lupinek C, Kundi M, Selb R, Niederberger V, Valenta R.
Reduction in allergen-specific IgE binding as measured by microarray: a
possible surrogate marker for effects of specific immunotherapy.Journal of Allergy and Clinical Immunology. 2015;136(3):806-809.
e807.
156. Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ. Pretreatment IgE
sensitization patterns determine the molecular profile of the IgG4
response during updosing of subcutaneous immunotherapy with timothy
grass pollen extract. Journal of Allergy and Clinical Immunology.2016;137(2):562-570.
157. Lichtenstein LM, Norman PS, Winkenwerder WL, Osler AG. In vitro
studies of human ragweed allergy: changes in cellular and humoral
activity associated with specific desensitization. The Journal of
clinical investigation. 1966;45(7):1126-1136.
158. Mothes N, Heinzkill M, Drachenberg K, et al. Allergen‐specific
immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced
seasonally boosted immunoglobulin E production and inhibition of
basophil histamine release by therapy‐induced blocking antibodies.Clinical & Experimental Allergy. 2003;33(9):1198-1208.
159. Niederberger V, Horak F, Vrtala S, et al. Vaccination with
genetically engineered allergens prevents progression of allergic
disease. Proceedings of the National academy of Sciences.2004;101(suppl 2):14677-14682.
160. Zieglmayer P, Focke-Tejkl M, Schmutz R, et al. Mechanisms, safety
and efficacy of a B cell epitope-based vaccine for immunotherapy of
grass pollen allergy. EBioMedicine. 2016;11:43-57.
161. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of
interleukin 10 in specific immunotherapy. The Journal of clinical
investigation. 1998;102(1):98-106.
162. Campana R, Moritz K, Marth K, et al. Frequent occurrence of T
cell–mediated late reactions revealed by atopy patch testing with
hypoallergenic rBet v 1 fragments. Journal of Allergy and Clinical
Immunology. 2016;137(2):601-609. e608.
163. Prausnitz C, Küstner H. Studien über die Überempfindlichkeit.Zentralbl Bakteriol. 1921;86:160-169.
164. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch
pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.Journal of Allergy and Clinical Immunology. 2008;122(5):951-960.
165. Scadding GW, Calderon MA, Shamji MH, et al. Effect of 2 Years of
Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response
to Allergen Challenge at 3 Years Among Patients With Moderate to Severe
Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.JAMA. 2017;317(6):615-625.
166. Mösges R, Koch A, Raskopf E, et al. Lolium perenne peptide
immunotherapy is well tolerated and elicits a protective B‐cell response
in seasonal allergic rhinitis patients. Allergy.2018;73(6):1254-1262.